Navigation Links
ACTOS Linked to Several Cardiovascular Benefits

Studies presented at the 42nd Annual Meeting of the European Association for the Study of Diabetes (EASD) has revealed that ACTOS? (pioglitazone HCl), an oral// antidiabetic medication, demonstrated significant cardiovascular benefits such as reducing the risk of heart attack and/or C and acute coronary syndrome in patients with type 2 diabetes.

Cardiovascular disease (CVD) is the leading cause of premature death in patients with diabetes. An estimated 171 million people worldwide have diabetes, and CVD is responsible for 50% to 80% of deaths in people with diabetes.

"We are continuing to see the benefits of ACTOS beyond glycemic control," said Erland Erdmann, M.D., chairman of the PROactive Executive Committee and director of the Clinic III for Internal Medicine, University of Cologne, Germany. "We know that patients with diabetes are two to four times more likely to develop heart disease or have a stroke than people without diabetes. The data presented at EASD showed that ACTOS can have a positive effect on several measures of cardiovascular disease outcomes in high-risk patients with type 2 diabetes."

Reduced Occurrence of Major Adverse Cardiovascular Events (MACE)

Results from one of the studies showed that ACTOS significantly reduced the occurrence of major adverse cardiovascular events (MACE), such as heart attacks, nonfatal stroke, acute coronary syndrome and cardiovascular death in high-risk patients with type 2 diabetes. Compared to placebo, patients treated with ACTOS demonstrated statistically significant risk reductions of heart attacks (23 percent, P=0.046), the combined risk of cardiovascular death, nonfatal heart attack or nonfatal stroke (18 percent, P=0.020) and the combined risk of all-cause mortality, nonfatal heart attack, nonfatal stroke or acute coronary syndrome (17 percent, P=0.010). These results were part of the landmark PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Event
'"/>




Page: 1 2 3 4

Related medicine news :

1. Low Cholesterol Linked to Severe Depression and Violent Behavior in Men
2. Cough Syrup Ingredient Linked to Stroke
3. Irregular Periods Linked to Diabetes
4. Hormones Linked To Migraines
5. Triglycerides Linked To Stroke Risk
6. Smoking Linked To Low Infant Birth Weight
7. Nausea Linked To Anxiety And Depression
8. Painkiller Linked to Deaths
9. High Levels of Protein Linked to Brain Shrinkage
10. Snoring Linked To Headaches
11. Hormone Therapy Linked to Dementia
Post Your Comments:
Breaking Medicine Technology:Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 2Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 3Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 4Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 5New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2Study to Investigate AHCC and the Swine Flu Virus 47555 1Study to Investigate AHCC and the Swine Flu Virus 47555 2Consumer Reports 3A Hearing Aid Shoppers Pay High Prices Get Mediocre Fittings 47551 1Consumer Reports 3A Hearing Aid Shoppers Pay High Prices Get Mediocre Fittings 47551 2Consumer Reports 3A Hearing Aid Shoppers Pay High Prices Get Mediocre Fittings 47551 3Consumer Reports 3A Hearing Aid Shoppers Pay High Prices Get Mediocre Fittings 47551 4PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 1PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 2PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 3PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 4PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 5PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 6